Sigma-Tau acquires additional rights to angioedema product from Dyax
This article was originally published in Scrip
Executive Summary
Dyax and Defiante Farmaceutica, a Sigma-Tau subsidiary, have expanded their 2010 partnership for Dyax's subcutaneous hereditary angioedema treatment, ecallantide, to include countries in Latin America and Southeast Asia.